CAR-T Congress USA | Kisaco Research
A Collaborative Approach to Maximise the Potential of CAR-T
Boston, USA
20-22 March, 2018
Download Agenda
The Audience
Register

Meeting Mojo

Meeting Mojo, the event networking platform, is now live!

Once you have registered for the conference, you will receive your login details by email. Click here to log-in.

Please do not hesitate to contact us if you have any questions.

Why Attend

The CAR-T Congress gathers thought leaders from biotech, big pharma, academia and investment to address the challenges and opportunities of CAR-T therapies in both liquid and solid tumors.  Discussing the potential of CARs in alternative cell types, mechanisms behind toxicity and tumor targeting, this event will provide an in depth view into this expansive area.

Exploring ground-breaking developments into CAR-T therapy, the event will provide the opportunity to collaborate to create a commercially viable, effective and safe therapy.  

Key session topics include:

  • Alternative cell constructs: TCRs, gamma delta T cells, CAR-NK & CAR-Tregs
  • Commercialisation, regulation & implementation
  • Safety, control & the underlying mechanisms of toxicity
  • Scalability, automation & process development
  • Target identification & neoantigen discovery
  • Patient access & strategic considerations
  • Investment & partnering workshops

Introducing dedicated partnering & networking sessions, with high level workshops to navigate the investment landscape & meet emerging companies. Join us for a rare opportunity to hear first-hand from those shaping the industry.

Take a look at our highlights video:

The Agenda

Simply fill in this form we'll send you a PDF version immediately. We need some information to know where to send the file and how to address our email to you.

CAR-T USA Agenda

Download Full Agenda

We need some information to know where to send the link and how to address our email to you. Please note, a link to the PDF will also become immediately available once this form is submitted.

To prevent automated spam submissions leave this field empty.

Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].

User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].

For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.

100+
Attendees
15+
Hours of Dedicated Networking Time
50:50
ratio of Academia to Industry
25+
Speakers
15+
1-to-1 Meetings Available per Attendee

The Speakers

 

Ronald Dudek

Living Pharma

Ronald Dudek

Living Pharma
 

Laurence Cooper

Chief Executive Officer
Ziopharm

Laurence Cooper

Chief Executive Officer
Ziopharm
 

Joern-Peter Halle

Senior Vice President, Head Translational Innovation Platform Immuno-Oncology and Head External Innovation
Merck KGaA

Peter is leading the Translational Innovation Platform Immuno-Oncology with global responsibility for the research, discovery, and translational aspects of Merck KGaA’s IO portfolio. As the global head for External Innovation he oversees the search & evaluation of external opportunities in all therapeutic areas ranging from academic collaborations to clinical assets. He is also responsible for innovation initiatives of the healthcare business and a member of the investment committee of Merck Venture, Merck KGaA’s corporate VC.

Joern-Peter Halle

Senior Vice President, Head Translational Innovation Platform Immuno-Oncology and Head External Innovation
Merck KGaA

Peter is leading the Translational Innovation Platform Immuno-Oncology with global responsibility for the research, discovery, and translational aspects of Merck KGaA’s IO portfolio. As the global head for External Innovation he oversees the search & evaluation of external opportunities in all therapeutic areas ranging from academic collaborations to clinical assets. He is also responsible for innovation initiatives of the healthcare business and a member of the investment committee of Merck Venture, Merck KGaA’s corporate VC. He started his carrier in Merck KGaA 12 years ago as a member of the corporate development. Prior to joining Merck KGaA, he co-founded a biotech company focusing on R&D in dermatology where he was responsible for IP, bioinformatics, and technology development and served as a Chief Business Officer.

 

Neil Sheppard

Head External Co-operations & Early Development Leader
GSK

Neil Sheppard

Head External Co-operations & Early Development Leader
GSK
 

Robert Hofmeister

Chief Scientific Officer
TCR2

Robert Hofmeister

Chief Scientific Officer
TCR2
 

Matthew Hewitt

Principal Scientist/Director - Tumor Microenvironment
Bellicum Pharmaceuticals

Matthew Hewitt

Principal Scientist/Director - Tumor Microenvironment
Bellicum Pharmaceuticals
 

Scott Ohanesian

Senior VP of Commercial Operations, Clinical Trial Logistics
QuickSTAT, A Quick Company

Mr. Scott Ohanesian has held executive roles over the past 14 years for Clinical Logistics Organizations and Contract Manufacturing Organizations (CMOs), managing global logistics for Phase I to Phase IV clinical trials.

He currently leads the QuickSTAT U.S. commercial operations team to build strategic relationships with pharmaceutical and biotech companies in order to provide comprehensive solutions for their global supply chain, ensuring product integrity and patient safety.  

Scott Ohanesian

Senior VP of Commercial Operations, Clinical Trial Logistics
QuickSTAT, A Quick Company

Mr. Scott Ohanesian has held executive roles over the past 14 years for Clinical Logistics Organizations and Contract Manufacturing Organizations (CMOs), managing global logistics for Phase I to Phase IV clinical trials.

He currently leads the QuickSTAT U.S. commercial operations team to build strategic relationships with pharmaceutical and biotech companies in order to provide comprehensive solutions for their global supply chain, ensuring product integrity and patient safety.  

Prior to joining QuickSTAT, Scott managed the Asia Pacific commercial operations for Marken Limited, where he implemented the commercial strategy for his company in key markets, such as Australia, China, India, Japan, Singapore, South Korea, and Taiwan.  Prior to that position, he was in a global strategic management role at a CMO, creating mutually beneficial partnership models. 

He is trained and well versed in Good Manufacturing Practices, (GMP) and has helped create innovative logistics solutions for numerous new drug products--from formulation development through to commercialization, for pharmaceutical and biotech companies.

Scott is a graduate of Boston College with a Bachelor of Science in Finance and a Masters of International Law in Diplomacy from The Fletcher School at Tufts University, with affiliated course work at Harvard Law School and Harvard Business School.

 

Dr Bijal Shah

MD Medical Oncology
Moffitt Cancer Center

Dr Bijal Shah

MD Medical Oncology
Moffitt Cancer Center
 

James Noble

CEO
Adaptimmune

James Noble

CEO
Adaptimmune
 

Bob Valamehr, PhD MBA,

Vice President, Cancer Immunotherapy
Fate Therapeutics Inc

Bob Valamehr, PhD MBA,

Vice President, Cancer Immunotherapy
Fate Therapeutics Inc
 

Andrew Allen

President & CEO,
Gritstone Oncology

Andrew Allen

President & CEO,
Gritstone Oncology
 

Dr David Sourdive, PhD

Executive Vice President Technical Operations
Cellectis

David Sourdive, Ph.D., is a co-founder of Cellectis and joined the Board of Directors in 2000. Dr. Sourdive holds the position of Executive Vice President, Technical Operations, with the mission to develop the Company’s industrial and technological basis as well as to deploy its operations in the pharmaceutical arena. Dr. Sourdive combines a strong scientific expertise with experience in managing industrial programs bringing innovative technologies to industrial fruition. He served as Executive Vice President, Corporate Development, from 2008 to 2016.

Dr David Sourdive, PhD

Executive Vice President Technical Operations
Cellectis

David Sourdive, Ph.D., is a co-founder of Cellectis and joined the Board of Directors in 2000. Dr. Sourdive holds the position of Executive Vice President, Technical Operations, with the mission to develop the Company’s industrial and technological basis as well as to deploy its operations in the pharmaceutical arena. Dr. Sourdive combines a strong scientific expertise with experience in managing industrial programs bringing innovative technologies to industrial fruition. He served as Executive Vice President, Corporate Development, from 2008 to 2016. In addition to his role at Cellectis, Dr. Sourdive has also served on the board of directors of the Mediterranean Institute for Life Sciences. David Sourdive graduated from École Polytechnique, received his Ph.D. in molecular virology at Institut Pasteur and completed a research fellowship in the Emory University Department of Microbiology and Immunology. His management training is from the HEC (Challenge +) and his decade-long experience in industrial program management was acquired at the French Department of Defense (DGA) prior to Cellectis’ inception.

 

Dr Yangbing Zhao

Director of the T Cell Engineering Laboratory (TCEL)
Center for Cellular Immunotherapies at the University of Pennsylvania.

Dr. Yangbing Zhao is the Director of the T Cell Engineering Laboratory (TCEL), Center for Cellular Immunotherapies at the University of Pennsylvania. He received an MD and PhD in Immunology from the Third Medical University in Chongqing, China. From 1996 – 2000, he was a visiting scientist at The Weizmann Institute of Science in Rehovot, Israel, where he studied tolerance induction through genetically engineered T cells for allogeneic bone marrow transplantation.

Dr Yangbing Zhao

Director of the T Cell Engineering Laboratory (TCEL)
Center for Cellular Immunotherapies at the University of Pennsylvania.

Dr. Yangbing Zhao is the Director of the T Cell Engineering Laboratory (TCEL), Center for Cellular Immunotherapies at the University of Pennsylvania. He received an MD and PhD in Immunology from the Third Medical University in Chongqing, China. From 1996 – 2000, he was a visiting scientist at The Weizmann Institute of Science in Rehovot, Israel, where he studied tolerance induction through genetically engineered T cells for allogeneic bone marrow transplantation. For the next two years he was a research associate at Duke University Medical Center, where he worked on RNA transfected dendritic cell vaccines against tumors. In 2003, he joined Dr. Steven Rosenberg’s group as a senior research fellow at the Surgery Branch of the National Cancer Institute, where his research work directly led to clinical trials of treating cancer patients with TCR or CAR engineered T cells against NY-ESO-1, Her2/Neu, CD19 or VEGFR. He joined the faculty of the Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine in 2009 as the Director of TCEL.  His Laboratory’s research and development work has led to multiple clinical trials for the treatment of solid tumors with genetically engineered T cells against mesothelioma, pancreatic cancer, breast cancer and glioblastoma. 

 

David Epstein

Chairman
Rubius Therapeutics & Executive Partner Flagship Pioneering

David Epstein

Chairman
Rubius Therapeutics & Executive Partner Flagship Pioneering
 

Gary C. Du Moulin, PhD

Adjunct Associate Professor of Regulatory Affairs
College of Pharmacy and Health Sciences University

Gary C. Du Moulin, PhD

Adjunct Associate Professor of Regulatory Affairs
College of Pharmacy and Health Sciences University
 

Lawrence Lamb

Co-Founder
Incysus

Lawrence Lamb

Co-Founder
Incysus
 

Michael Klichinsky

Co-Founder
CARMA Therapeutics

Michael Klichinsky

Co-Founder
CARMA Therapeutics
 

Stephane Boissel

CEO
TxCell

Stephane Boissel

CEO
TxCell
 

Russell Cruz

Assistant Professor
Children’s National Medical Center

Russell Cruz

Assistant Professor
Children’s National Medical Center

Expertise Partner

Thought Leadership Partners

Event Partners

Media partners

Become a Sponsor

This summit offers attendees, sponsors, and event partners access to representatives from the entire ecosystem, delivering unique business development opportunities.

Position your organization as a leader in this marketplace and leverage bespoke business development and marketing strategies.

Contact our sponsorship team to find out more about each package by emailing [email protected] or by calling: +44 (0)20 3696 2920.

CAR-T Congress USA

March 20 - 22, 2018

Boston | MA

Visit www.car-tcongress.com

Venue

Hilton Boston Dedham Hotel, 25 Allied Drive, Dedham, MA, 0206

Hilton_Boston

Overlooking tranquil woods, and only 10 miles from downtown Boston, this year we've chosen the newly-renovated Hilton Boston/Dedham as our venue of choice.

Located off I-95, it is within close proximity to multiple train stations and there is a complimentary shuttle service allowing you to travel around easily.

Inside the hotel you’ll find modern and welcoming rooms and suites, great recreational amenities, vibrant local cuisine and stunning indoor/outdoor spaces. Book a room for only $109.00 + tax (based on single occupancy).

Book now

T: +1-781-329-7900

Remember to always quote “CART” when booking.

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

Preparing registration...

Resources

Download Resource

We need some information to know where to send the link and how to address our email to you. Please note, a link to the PDF will also become immediately available once this form is submitted.

To prevent automated spam submissions leave this field empty.

Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].

User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].

For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us

We need some information to know how best to respond to your request below.

To prevent automated spam submissions leave this field empty.

Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].

User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].

For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.